Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMIVGOR)

Drug Name
sarcosine Drug Info
Synonyms
sarcosine; 107-97-1; N-methylglycine; Sarcosinic acid; Methylglycine; Glycine, N-methyl-; Methylaminoacetic acid; 2-(methylamino)acetic acid; N-Methylaminoacetic acid; Sarcosin; (Methylamino)acetic acid; (Methylamino)ethanoic acid; Sargosine hydrochloride; N-Methyl glycine; Acetic acid, (methylamino)-; Cocoylsarcosine; Polysarcosine; N-methyl-Glycine; H-Sar-OH; UNII-Z711V88R5F; BRN 1699442; Sarcosine, 98%; AI3-15410; Methylamino-Acetic Acid; EINECS 203-538-6; SAR; CHEMBL304383; CHEBI:15611; FSYKKLYZXJSNPZ-UHFFFAOYSA-N; Z711V88R5F
Cross-matching ID
PubChem CID
1088
ChEBI ID
CHEMBL15611
CAS Number
CAS 107-97-1
TTD Drug ID
D0YF9S
VARIDT Drug ID
DR00326

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.01 7.31e-3 34/36 (94.44%) PCNA;MCM2;MCM4;...
Spliceosome 2.00 3.66e-3 101/150 (67.33%) PUF60;HNRNPM;DHX15;...
Natural killer cell mediated cytotoxicity -1.75 3.56e-2 99/131 (75.57%) RAC2;MAP2K2;BID;...
Hematopoietic cell lineage -1.79 2.49e-2 90/99 (90.91%) CD5;ITGB3;IL6R;...
Th17 cell differentiation -1.84 1.25e-2 95/107 (88.79%) NFATC1;IL21R;HLA-DOA;...
Apoptosis -1.84 1.56e-2 126/168 (75%) RELA;MAP2K2;BID;...
Graft-versus-host disease -1.89 1.66e-2 32/42 (76.19%) HLA-DPA1;HLA-DRB1;HLA-A;...
Mitophagy -2.03 6.23e-3 56/68 (82.35%) BCL2L1;TFEB;MAPK10;...
Th1 and Th2 cell differentiation -2.04 1.25e-2 80/92 (86.96%) NFATC1;RUNX3;HLA-DOA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H